The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care
- PMID: 36599918
- PMCID: PMC9902467
- DOI: 10.1038/s41416-022-02107-8
The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care
Erratum in
-
Correction to: The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care.Br J Cancer. 2023 Jan;128(2):399. doi: 10.1038/s41416-023-02160-x. Br J Cancer. 2023. PMID: 36697967 Free PMC article. No abstract available.
Abstract
Genomic screening is routinely used to guide the treatment of cancer patients in many countries. However, several multi-layered factors make this effort difficult to deliver within a clinically relevant timeframe. Here we share the learnings from the CRUK-funded Stratified Medicine Programme for advanced NSCLC patients, which could be useful to better plan future studies.
© 2023. The Author(s).
Conflict of interest statement
SMM has received compensation as a member of the scientific advisory board of AstraZeneca. GM received honoraria for advisory boards/speaker engagements from BMS, MSD, AZ, Roche, D2G, Servier and Merck Serono. Prof Swanton acknowledges grant support from Pfizer, AstraZeneca, BMS, Roche-Ventana, Boehringer-Ingelheim, Invitae (previously Archer Dx Inc)—collaboration in minimal residual disease sequencing technologies, and Ono Pharmaceutical, and is an AstraZeneca Advisory Board member and Chief Investigator for the AZ MeRmaiD 1 and 2 clinical trials and is also Co-Chief Investigator of the NHS Galleri trial funded by GRAIL and a paid member of GRAIL’s Scientific Advisory Board. He receives consultant fees from Achilles Therapeutics (also SAB member), Bicycle Therapeutics (also a SAB member), Genentech, Medicxi, Roche Innovation Centre—Shanghai, Metabomed (until July 2022) and the Sarah Cannon Research Institute C.S has received honoraria from Amgen, AstraZeneca, Pfizer, Novartis, GlaxoSmithKline, MSD, Bristol Myers Squibb, Illumina and Roche-Ventana; had stock options in Apogen Biotechnologies and GRAIL until June 2021, and currently has stock options in Epic Bioscience, Bicycle Therapeutics, and has stock options and is co-founder of Achilles Therapeutics (Patents: C.S. holds patents relating to assay technology to detect tumour recurrence (PCT/GB2017/053289); to targeting neoantigens (PCT/EP2016/059401), identifying patent response to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221), identifying patients who respond to cancer treatment (PCT/GB2018/051912), US patent relating to detecting tumour mutations (PCT/US2017/28013), methods for lung cancer detection (US20190106751A1) and both a European and US patent related to identifying insertion/deletion mutation targets (PCT/GB2018/051892)). SP reported receiving consultancy honoraria and research funding from Amgen, AstraZeneca, Blueprint, BMS, Boehringer Ingelheim, Daiichi Sankyo, GlaxoSmithKline, Guardant Health, Janssen, Lilly, MSD, Roche, Seattle Genetics, Takeda, Turning Point Therapeutics; consultancy honoraria from Bayer, BeiGene, EQRx, Merck KGaA, Novartis, Pfizer and Sanofi; he is an advisor for ALK Positive UK, Lung Cancer Europe, Ruth Strauss Foundation; part of the board of directors of Mesothelioma Applied Research Foundation and leadership for BTOG Steering Committee, ETOP Foundation Council. MR and DMB are employees of Illumina, a public company that develops and markets systems for genetic analysis. SNH is an employee of Pfizer. SH is a full-time employee of AstraZeneca and holds stock in AstraZeneca and Roche/Genentech. JP was an employee of Illumina during the programme. The remaining authors declare no competing interests.
Figures

References
Publication types
MeSH terms
Grants and funding
- A22792/CRUK_/Cancer Research UK/United Kingdom
- 25354/CRUK_/Cancer Research UK/United Kingdom
- 22209/CRUK_/Cancer Research UK/United Kingdom
- A22803/CRUK_/Cancer Research UK/United Kingdom
- A26796/CRUK_/Cancer Research UK/United Kingdom
- A22788/CRUK_/Cancer Research UK/United Kingdom
- A22795/CRUK_/Cancer Research UK/United Kingdom
- 19363/CRUK_/Cancer Research UK/United Kingdom
- A26792/CRUK_/Cancer Research UK/United Kingdom
- A22798/CRUK_/Cancer Research UK/United Kingdom
- A22800/CRUK_/Cancer Research UK/United Kingdom
- A22793/CRUK_/Cancer Research UK/United Kingdom
- A22801/CRUK_/Cancer Research UK/United Kingdom
- A22786/CRUK_/Cancer Research UK/United Kingdom
- A22802/CRUK_/Cancer Research UK/United Kingdom
- A26790/CRUK_/Cancer Research UK/United Kingdom
- A26797/CRUK_/Cancer Research UK/United Kingdom
- A22790/CRUK_/Cancer Research UK/United Kingdom
- A22808/CRUK_/Cancer Research UK/United Kingdom
- A22791/CRUK_/Cancer Research UK/United Kingdom
- A22796/CRUK_/Cancer Research UK/United Kingdom
- A22787/CRUK_/Cancer Research UK/United Kingdom
- A26798/CRUK_/Cancer Research UK/United Kingdom
LinkOut - more resources
Full Text Sources
Medical